Syros Pharmaceuticals, Inc. (SYRS)
OTCMKTS · Delayed Price · Currency is USD
0.0008
+0.0004 (100.00%)
Nov 3, 2025, 4:00 PM EST
Syros Pharmaceuticals Employees
Syros Pharmaceuticals had 68 employees as of December 31, 2023. The number of employees decreased by 49 or -41.88% compared to the previous year.
Employees
68
Change (1Y)
-49
Growth (1Y)
-41.88%
Revenue / Employee
$5,676
Profits / Employee
-$1,438,456
Market Cap
21.47K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 68 | -49 | -41.88% |
| Dec 31, 2022 | 117 | -7 | -5.65% |
| Dec 31, 2021 | 124 | 21 | 20.39% |
| Dec 31, 2020 | 103 | 20 | 24.10% |
| Dec 31, 2019 | 83 | 7 | 9.21% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
Syros Pharmaceuticals News
- 7 months ago - Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - Seeking Alpha
- 8 months ago - Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration - Business Wire
- 1 year ago - Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
- 1 year ago - Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression - Business Wire
- 1 year ago - The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions - Accesswire
- 1 year ago - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm - Accesswire
- 1 year ago - The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations - Accesswire
- 1 year ago - Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript - Seeking Alpha